Filing Overview
This Form 8-K was filed by Vallon Pharmaceuticals, Inc. on May 9, 2022, reporting the issuance of a press release covering financial results for the quarter ended March 31, 2022, and a business update. The request metadata identifies GRI Bio, Inc., but the filing itself identifies Vallon Pharmaceuticals, Inc. as the registrant.
Financial and Operating Information
The filing text does not include the financial-results press release furnished as Exhibit 99.1. Accordingly, it does not provide clear values for revenue, net income or loss, operating expenses, cash flow, margins, debt, cash, liquidity, or other financial metrics.
Changes Versus Prior Period
The filing does not provide sufficient financial data to assess changes versus the comparable prior-year period or the immediately preceding quarter.
Guidance, Outlook, Risks, and Unusual Items
The filing states that a business update was provided in the accompanying press release, but the press-release content is not included in the supplied filing text. No clear guidance, outlook, risk updates, contingencies, or unusual items can therefore be summarized.
The information, including Exhibit 99.1, was furnished rather than filed for purposes of Section 18 of the Securities Exchange Act and was not incorporated by reference into other SEC filings.
Key Facts to Verify
- Obtain and review Exhibit 99.1 for the quarter ended March 31, 2022 financial statements and business update.
- Verify quarterly cash, operating cash burn, liquidity runway, debt, and financing activity.
- Verify revenue, net loss, operating expenses, and comparable-period changes.
- Review management’s development-program updates, guidance, contingencies, and risk disclosures.
- Confirm the applicable registrant, since the supplied metadata names GRI Bio, Inc., while the filing names Vallon Pharmaceuticals, Inc.